Shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) have been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $4.25.
ATNM has been the topic of a number of analyst reports. Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 4th. Zacks Investment Research downgraded Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 4th. Finally, William Blair initiated coverage on Actinium Pharmaceuticals in a report on Thursday, August 8th. They issued an “outperform” rating on the stock.
Shares of NYSEAMERICAN:ATNM traded down $0.01 on Thursday, reaching $0.21. The company had a trading volume of 545,400 shares, compared to its average volume of 1,092,915. Actinium Pharmaceuticals has a 52-week low of $0.20 and a 52-week high of $0.87.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Recommended Story: Convertible Shares
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.